Cargando…

Examination of the effectiveness of local therapy for oligo‐recurrence of EGFR‐mutated NSCLC

BACKGROUND: The effectiveness of local therapy has been reported in patients with oligo‐recurrence of non‐small cell lung cancer (NSCLC), a metachronous recurrence with a limited number of recurrences, which can be treated with local therapy. Conversely, remarkable progress has been made in systemic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonoda, Dai, Kondo, Yasuto, Maruyama, Raito, Hayashi, Shoko, Naito, Masahito, Mikubo, Masashi, Matsui, Yoshio, Shiomi, Kazu, Satoh, Yukitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008676/ https://www.ncbi.nlm.nih.gov/pubmed/36720507 http://dx.doi.org/10.1111/1759-7714.14805

Ejemplares similares

Spontaneous non-traumatic mediastinal hematoma associated with oral anticoagulant therapy: A case report and literature review
por: Mikubo, Masashi, et al.
Publicado: (2017)

Prognostic implications of prostaglandin E-major urinary metabolite in resected non-small-cell lung cancer
por: Mikubo, Masashi, et al.
Publicado: (2023)

Abnormal branching of the left lingular pulmonary artery diagnosed by three-dimensional computed tomographic angiography in a patient with lung cancer: a case report
por: Sonoda, Dai, et al.
Publicado: (2016)

Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer
por: Shiomi, Kazu, et al.
Publicado: (2017)

Factors associated with lymph node metastasis upstage after resection for patients with micropapillary lung adenocarcinoma
por: Matsushima, Keigo, et al.
Publicado: (2021)

Comparison between quantitative computed tomography, scintigraphy, and anatomical methods for prediction of postoperative FEV(1) and DLCO: effects of chronic obstructive pulmonary disease status and resected lobes
por: Yokoba, Masanori, et al.
Publicado: (2020)

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy
por: Kusuhara, Seiichiro, et al.
Publicado: (2021)

Report of a rare case: occult hemothorax due to blunt trauma without obvious injury to other organs
por: Ogawa, Fumihiro, et al.
Publicado: (2013)

Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
por: Sato, Miyuki, et al.
Publicado: (2019)

Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure
por: Sonoda, Dai, et al.
Publicado: (2020)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Miyawaki, Taichi, et al.
Publicado: (2021)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Free Tensor Fascia Lata Flap and Synthetic Mesh Reconstruction for Full-Thickness Chest Wall Defect
por: Ono, Jumpei, et al.
Publicado: (2013)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers
por: Ryuge, Shinichiro, et al.
Publicado: (2017)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Current Approaches in NSCLC Targeting K-RAS and EGFR
por: Aran, Veronica, et al.
Publicado: (2019)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH
por: Swiatnicki, Matthew R., et al.
Publicado: (2022)

Heterogeneous distribution of EGFR mutation in NSCLC: Case report
por: Boukansa, Sara, et al.
Publicado: (2023)

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
por: Yan, Dan
Publicado: (2023)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

OligoRAP – an Oligo Re-Annotation Pipeline to improve annotation and estimate target specificity
por: Neerincx, Pieter BT, et al.
Publicado: (2009)

Polar tagging in the synthesis of monodisperse oligo(p-phenyleneethynylene)s and an update on the synthesis of oligoPPEs
por: Sahoo, Dhananjaya, et al.
Publicado: (2010)

Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma
por: Kondo, Yasuto, et al.
Publicado: (2022)

Oligo‐Quinolylene–Vinylene Foldamers
por: Wang, Jinhua, et al.
Publicado: (2020)

Nano-RNases: oligo- or dinucleases?
por: Lee, Vincent T, et al.
Publicado: (2022)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m5i99hjmjlh9tjg29p9sn1rce6